medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2012, Number 603

<< Back Next >>

Rev Med Cos Cen 2012; 69 (603)

Diagnóstico de síndrome de ovario poliquístico

Vallecillo TA

Language: Spanish
References: 17
Page: 431-434
PDF size: 234.97 Kb.


ABSTRACT

Polycystic ovary syndrome is the most common endocrinopathy in women, has also been associated with 75% of cases with anovulatory infertility. It was known in 1935 as “Stein-Leventhal syndrome,” because these researchers described for the first time the association between amenorrhea and polycystic ovaries. Currently, there are two trends in the diagnosis of PCOS, the proposal of the National Institute of Health (NIH) established since 1990 and the Rotterdam criteria, created in 2003.


REFERENCES

  1. ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2009 Oct;114(4):936-49.

  2. Azziz, R. The evaluation and Management of hirsutism. Obstet & Gynecol. 2003 May; 101(5) part 1:995- 1007.

  3. Battagia, C. et al. The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome. AJOG. 1995;172.108-113.

  4. Carmina, E. et al. the diagnosis of polycystic ovary syndrome in adolescents .AJOG. 2010;203.201-202.

  5. Costello, M. y Eden, J. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003 Jan;79(1):1-13.

  6. Fauser, B. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop. Group Fertil Steril. 2012;97(1):28–38.

  7. Fernández-Morales Donald. Manifestaciones clínicas del síndrome del ovario poliquístico. Acta méd. costarric. 2005 Oct;47(4):180-185.

  8. Fratantonio, E; Vicari, E. et al. Genetics of polycystic ovarian syndrome. Reproductive BioMedicine Online. 2005;10(6):713-720.

  9. Goodarzi MO. Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med. 2008 Jan;26(1):5-13

  10. Hernández Sampieri, R. y colaboradores. Metodología de la investigación. Quinta edición. 2010. Editorial McGraw-Hill Interamericana Editores S.A. de C.V.

  11. Kauffman, R. et al. Polycystic ovarian syndrome and insulin resistance in white and Mexican American: A comparison of two distinct populations. AJOG.2002. vol.187,1362-1369.

  12. Lamb, J. et al. Physical activity in women with polycystic ovary syndrome: prevalence, predictors, and positive health associantions.2011; 204.352-354.

  13. Mathur, R. et al. Use of metformin in polycystic ovary syndrome. AJOG. 2008;199,596-607.

  14. Mor, E. et al. The insulin resistant subphenotype of polycystic ovary syndrome: Clinical parameters and pathogenesis. AJOG 2004;190,1654-60.

  15. Norman, R. et al. Polycystic ovary syndrome The Lancet. 2007.Vol.370, 685-693.

  16. Pineda Elia y De Alvarado Eva Luz. Metodología de la investigación. 3ra edición. 2008. Organización Panamericana de la Salud. Washington, D.C.

  17. Yildiz B. et al. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002 Aug;87(8):3871-5.




2020     |     www.medigraphic.com